A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma

Sean Warsch, Peter Hosein, Lauren S. Maeda, Ash A. Alizadeh, Izidore Lossos

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Bendamustine is approved in the United States for relapsed indolent lymphoma. However, it has not been widely studied in mantle cell lymphoma (MCL). We retrospectively reviewed the records of all patients with MCL who were treated with bendamustine at three centers. The primary endpoint was overall response rate (ORR). Thirty patients with MCL received bendamustine, 25 for relapsed disease. After a median follow-up of 12 months, there were 15 complete responses (CRs) with an ORR of 83% (95% confidence interval [CI] 70-97%). Factors significantly associated with longer survival were achieving a CR and classical (versus blastic) variant of MCL. Grade 3 or 4 neutropenia, anemia and thrombocytopenia occurred in 23%, 3% and 20%, respectively. There was one case of progressive multifocal leukoencephalopathy 10 months after therapy completion. Bendamustine in combination with rituximab demonstrated a high response rate in this study of patients with predominantly relapsed MCL.

Original languageEnglish
Pages (from-to)1299-1305
Number of pages7
JournalLeukemia and Lymphoma
Volume53
Issue number7
DOIs
StatePublished - Jul 1 2012

Fingerprint

Mantle-Cell Lymphoma
Retrospective Studies
Safety
Progressive Multifocal Leukoencephalopathy
Therapeutics
Neutropenia
Thrombocytopenia
Anemia
Lymphoma
Bendamustine Hydrochloride
Confidence Intervals
Survival

Keywords

  • bendamustine
  • chemotherapy
  • mantle cell lymphoma
  • Non-Hodgkin lymphoma
  • rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. / Warsch, Sean; Hosein, Peter; Maeda, Lauren S.; Alizadeh, Ash A.; Lossos, Izidore.

In: Leukemia and Lymphoma, Vol. 53, No. 7, 01.07.2012, p. 1299-1305.

Research output: Contribution to journalArticle

@article{ecacb4e6fb344b66a0565667b5b67612,
title = "A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma",
abstract = "Bendamustine is approved in the United States for relapsed indolent lymphoma. However, it has not been widely studied in mantle cell lymphoma (MCL). We retrospectively reviewed the records of all patients with MCL who were treated with bendamustine at three centers. The primary endpoint was overall response rate (ORR). Thirty patients with MCL received bendamustine, 25 for relapsed disease. After a median follow-up of 12 months, there were 15 complete responses (CRs) with an ORR of 83{\%} (95{\%} confidence interval [CI] 70-97{\%}). Factors significantly associated with longer survival were achieving a CR and classical (versus blastic) variant of MCL. Grade 3 or 4 neutropenia, anemia and thrombocytopenia occurred in 23{\%}, 3{\%} and 20{\%}, respectively. There was one case of progressive multifocal leukoencephalopathy 10 months after therapy completion. Bendamustine in combination with rituximab demonstrated a high response rate in this study of patients with predominantly relapsed MCL.",
keywords = "bendamustine, chemotherapy, mantle cell lymphoma, Non-Hodgkin lymphoma, rituximab",
author = "Sean Warsch and Peter Hosein and Maeda, {Lauren S.} and Alizadeh, {Ash A.} and Izidore Lossos",
year = "2012",
month = "7",
day = "1",
doi = "10.3109/10428194.2011.649476",
language = "English",
volume = "53",
pages = "1299--1305",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma

AU - Warsch, Sean

AU - Hosein, Peter

AU - Maeda, Lauren S.

AU - Alizadeh, Ash A.

AU - Lossos, Izidore

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Bendamustine is approved in the United States for relapsed indolent lymphoma. However, it has not been widely studied in mantle cell lymphoma (MCL). We retrospectively reviewed the records of all patients with MCL who were treated with bendamustine at three centers. The primary endpoint was overall response rate (ORR). Thirty patients with MCL received bendamustine, 25 for relapsed disease. After a median follow-up of 12 months, there were 15 complete responses (CRs) with an ORR of 83% (95% confidence interval [CI] 70-97%). Factors significantly associated with longer survival were achieving a CR and classical (versus blastic) variant of MCL. Grade 3 or 4 neutropenia, anemia and thrombocytopenia occurred in 23%, 3% and 20%, respectively. There was one case of progressive multifocal leukoencephalopathy 10 months after therapy completion. Bendamustine in combination with rituximab demonstrated a high response rate in this study of patients with predominantly relapsed MCL.

AB - Bendamustine is approved in the United States for relapsed indolent lymphoma. However, it has not been widely studied in mantle cell lymphoma (MCL). We retrospectively reviewed the records of all patients with MCL who were treated with bendamustine at three centers. The primary endpoint was overall response rate (ORR). Thirty patients with MCL received bendamustine, 25 for relapsed disease. After a median follow-up of 12 months, there were 15 complete responses (CRs) with an ORR of 83% (95% confidence interval [CI] 70-97%). Factors significantly associated with longer survival were achieving a CR and classical (versus blastic) variant of MCL. Grade 3 or 4 neutropenia, anemia and thrombocytopenia occurred in 23%, 3% and 20%, respectively. There was one case of progressive multifocal leukoencephalopathy 10 months after therapy completion. Bendamustine in combination with rituximab demonstrated a high response rate in this study of patients with predominantly relapsed MCL.

KW - bendamustine

KW - chemotherapy

KW - mantle cell lymphoma

KW - Non-Hodgkin lymphoma

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=84862728885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862728885&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.649476

DO - 10.3109/10428194.2011.649476

M3 - Article

VL - 53

SP - 1299

EP - 1305

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -